Bill Harvey: A.O.R.
Author: Bill Harvey
Over recent months, we have featured a number of articles highlighting some of the new roles that optometrists are currently taking on and are increasingly likely to become involved with in the future.
I believe the use of laser treatments will eventually fall into the optometrist’s job description. Indeed, many hospital optometrists are currently undertaking such procedures as selective laser trabeculoplasty and YAG capsulotomy. And with courses planned for training community-based optometrists in these procedures, such as the one already scheduled (and fully booked) to take place in Bristol just before Christmas, it is just a matter of time until laser treatment hits the primary care practices.
Thanks to David Bennett for picking up on a sentence in our CET concerning YAG laser use. In this, it was claimed that PXE is a common cause of zonular weakness, and therefore problematic for YAG treatment. This should, in fact, have read PXF. Pseudoexfoliation syndrome, often abbreviated as PEX and sometimes as PES or PXS, is a common cause of zonular weakness. In the US, it is sometimes abbreviated as PXF syndrome. PXE, or pseudoxanthoma elasticum, on the other hand, is now thought to be a rare cause of complication as it may result in increased zonular fibrin and anterior zonular displacement, such as occurs with Marfan syndrome, and may present a risk for those having YAG capsulotomy.
Those of you who agreed with one-time editor of the Manchester Guardian, who once said, ‘Television? No good will come of this device. The word is half Greek and half Latin,’ will, I hope, enjoy this week’s CET about pharmacovigilance. This term is one I believe we will all have to become very familiar with in the coming years. Acronymophobic (ANP) readers may wish to avoid.